0000000000281969

AUTHOR

S Zaun

showing 5 related works from this author

COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adju…

2014

5 Office-based Professional Association Gynecologic Oncologists e.V. in Germany (BNGO e.V.), Berlin; 6 Background: This prospective study evaluated the relationship between arthralgia and compliance during the first year of adjuvant anastrozole therapy in postmenopausal women with hormone receptor-positive early breast cancer. Patients and methods: COMPliance and Arthralgia in Clinical Therapy (COMPACT) was an open-label, multicenter, noninterventional study conducted in Germany. Patients had started adjuvant anastrozole 3-6 months before the study start. The primary end points were arthralgia, compliance, and the relationship between compliance and arthralgia, assessed at specific time poi…

musculoskeletal diseasesmedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentSpecific timeAnastrozoleBreast NeoplasmsAnastrozoleMedication AdherenceBreast cancerInternal medicineNitrilesmedicineHumansProspective Studiesskin and connective tissue diseasesProspective cohort studyAgedbusiness.industryDrug SubstitutionIncidence (epidemiology)IncidenceHematologyMiddle AgedTriazolesmedicine.diseaseArthralgiaSurgeryCompliance (physiology)Clinical therapyTreatment OutcomeOncologyChemotherapy AdjuvantFemalebusinessAdjuvantmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Info…

2019

<b><i>Background:</i></b> Breast cancer patients’ self-understanding of their disease can impact their quality of life (QoL); the relationship between compliance and QoL is poorly understood. <b><i>Patients and Methods:</i></b> The Patient’s Anastrozole Compliance to Therapy (PACT) program, a prospective, randomized study, investigated the effect of additional patient information material (IM) packages on compliance with adjuvant aromatase inhibitor (AI) therapy in postmenopausal women with hormone receptor-positive early breast cancer. The QoL subanalysis presented here examined the impact of IM packages on QoL and the association between QoL…

medicine.medical_specialtymedicine.drug_classAnastrozoleDiseasePactlaw.invention03 medical and health sciences0302 clinical medicineBreast cancerQuality of lifeRandomized controlled triallawmedicine030212 general & internal medicineAromatase inhibitorbusiness.industryCancermedicine.diseasehumanitiesOncology030220 oncology & carcinogenesisPhysical therapySurgerybusinessResearch Articlemedicine.drugBreast Care
researchProduct

AB1394 Compliance and arthralgias in clinical therapy (compact): Assessment of the incidence of arthralgia, therapy costs and compliance within the f…

2013

Background Aromatase inhibitors (AI) are well established as adjuvant endocrine treatment for postmenopausal women with hormone receptor-positive (HR+) early breast cancer (EBC). Drug-induced myalgia or arthralgia is among the most frequently reported adverse drug reactions to AIs. Objectives Little is known about the pathomechanism by which AIs cause muscle and joint injury. The literature on skeletal muscle complaints with AIs is confusing, in part because of a lack of clear definitions. Myalgia/arthralgia is defined as muscle/joint pain and is likely to affect patients’ quality of life and compliance with AI medication . We designed a prospective trial to collect real world data on the e…

musculoskeletal diseasesmyalgiamedicine.medical_specialtybusiness.industryIncidence (epidemiology)ImmunologyAnastrozolemedicine.diseaseGeneral Biochemistry Genetics and Molecular Biologybody regionsTherapy complianceBreast cancerRheumatologyQuality of lifeInternal medicineJoint painConcomitantmedicinePhysical therapyImmunology and Allergymedicine.symptombusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program o…

2013

BACKGROUND Compliance and persistence are often overlooked in adjuvant breast cancer treatment. PATIENTS AND METHODS PACT was a prospective, multicenter, randomized, open, parallel-group study assessing whether educational materials (EMs) enhanced compliance with aromatase inhibitor (AI) therapy in postmenopausal women with early, hormone-receptor-positive (HR+) breast cancer. The primary end points were compliance (proportion taking ≥ 80% anastrozole) at 12 months and persistence (proportion reporting anastrozole intake during the study period). RESULTS Four thousand eight hundred and forty-four patients were randomly assigned 1:1 to receive standard therapy or standard therapy with EMs. T…

medicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classmedicine.medical_treatmentAnastrozoleBreast NeoplasmsAnastrozolePactPersistence (computer science)Medication AdherenceEosinophilia–myalgia syndromeBreast cancerInternal medicineNitrilesmedicineHumansProspective StudiesEarly Detection of CancerAgedGynecologyAromatase inhibitorbusiness.industrySurrogate endpointHematologyMiddle AgedTriazolesmedicine.diseasePostmenopauseOncologyPatient ComplianceFemalebusinessAdjuvantmedicine.drugFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Compliance and arthralgias in clinical therapy (COMPACT): Assessment of the incidence of arthralgia, therapy costs, and compliance in the first year …

2012

e11040^ Background: Aromatase Inhibitors (AI) are well established as adjuvant endocrine treatment for postmenopausal women with HR+ early breast cancer (EBC). However, clinical trial data show higher frequently of arthralgia with AI than tamoxifen. As arthralgia may be greatly influencing compliance to adjuvant therapy, we designed a prospective trial to collect real world data on the effects of AI-associated arthralgia on patient compliance, patient outcomes and treatment costs of arthralgia. Methods: COMPACT is an open, prospective non-interventional study (NCT00857012) assessing the incidence of arthralgia, therapy costs, and compliance within the first year of adjuvant anastrozole (AN…

musculoskeletal diseasesCancer Researchmedicine.medical_specialtybiologybusiness.industrymedicine.medical_treatmentIncidence (epidemiology)Anastrozolebody regionsClinical trialCompliance (physiology)Clinical therapyOncologyInternal medicinemedicinebiology.proteinEndocrine systemAromataseskin and connective tissue diseasesbusinessAdjuvantmedicine.drugJournal of Clinical Oncology
researchProduct